Cell Source

Cell Source Revenue

The revenue of Cell Source (CLCS) as of Nov 17, 2026.

Revenue

0.00USD

Last updated:

In 2024, Cell Source's sales reached 0.00 USD, a % difference from the 0.00 USD sales recorded in the previous year.

The Cell Source Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
The Cell Source Revenue history
YEARRevenueYoY
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Source Revenue

Cell Source Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 USD
-2.01 M USD
-2.12 M USD
Jan 1, 2019
0.00 USD
-3.81 M USD
-4.48 M USD
Jan 1, 2020
0.00 USD
-3.64 M USD
-5.50 M USD
Jan 1, 2021
0.00 USD
-4.02 M USD
-5.47 M USD
Jan 1, 2022
0.00 USD
-4.18 M USD
-5.17 M USD
Jan 1, 2023
0.00 USD
-4.18 M USD
-5.17 M USD
Jan 1, 2024
0.00 USD
-3.85 M USD
-4.77 M USD
Jan 1, 2025
0.00 USD
-2.73 M USD
-4.64 M USD

Cell Source Margins

Cell Source stock margins

The Cell Source margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cell Source. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cell Source.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
- %
- %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %

Cell Source Stock analysis

What does Cell Source do? Cell Source, Inc. generates revenue through the development and commercialization of its Veto Cell immune system management technology, which selectively blocks immune responses in allogeneic hematopoietic stem cell transplantation (HSCT). The company's lead product, Veto Cell technology, is in pre-clinical phase and targets haploidentical stem cell transplants under mild conditioning regimens. Its product pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary, Cell Source Limited (CSL), supports these initiatives. Cell Source, Inc. focuses on developing immune tolerance biotechnology for clinical applications, targeting healthcare providers and transplant centers that require solutions for immune response management. The company's Veto Cell technology aims to enable safer and more effective allogeneic HSCT procedures, particularly for patients needing haploidentical transplants. The firm's pipeline products, including VETO CAR-T and Veto Cell kidney and liver transplants, are designed to address unmet needs in oncology and organ transplantation markets. The company's revenue model relies on the future commercialization of its proprietary technologies, with Veto Cell technology as the cornerstone. Its pre-clinical stage products, such as VETO CAR-T for B-cell malignancies and Veto Cell liver transplants, are positioned to enter clinical trials and eventually reach the market. Cell Source Limited (CSL) operates as a wholly owned subsidiary to advance these therapeutic approaches within the cell therapy sector. Cell Source is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Cell Source's Sales Figures

The sales figures of Cell Source originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Cell Source’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Cell Source's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Cell Source’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Cell Source stock

On Eulerpool you can find the complete historical development of The revenue Cell Source since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Cell Source historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cell Source

All Key Metrics — Cell Source